Novo Nordisk to launch connected insulin pens
Many diabetes patients have been calling for ‘smart’, internet-connected pens to monitor their condition, but the technology has been slow to arrive.
Now, Novo Nordisk has announced that it will globally launch two ‘connected’ insulin pens, which will be able to communicate with continuous glucose monitoring (CGM) systems and blood glucose meters (BGM).
This looks to be the start of the long-awaited digital integration, which has been held back by safety concerns, competitive interests and incompatible digital platforms.
Novo Nordisk’s biggest competitors in diabetes injectables are Eli Lilly and Sanofi, but looks to be ahead of its rivals in rolling out a joined-up digital solution, announcing plans to make two durable, connected insulin pens NovoPen 6 and NovoPen Echo Plus commercially available across key markets from early 2019.
In addition to demand from patients, healthcare payers, especially in the US, are calling for comprehensive disease management platforms.
Reactions
(4)
No comment yet.
Sign up to comment